These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 21305539

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 3. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
    Kim SJ, Taguchi T, Shimazu K, Tanji Y, Tamaki Y, Noguchi S.
    Oncology; 2009 Jun 04; 77(2):134-9. PubMed ID: 19628951
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2000 Jul 12; 6(7):2751-8. PubMed ID: 10914720
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
    Nakamura S, Ando M, Masuda N, Aogi K, Ino H, Iwata H, Tokuda Y, Yamamoto N, Kasai H, Takeuchi M, Tsuda H, Akiyama F, Kurosumi M, Fujiwara Y.
    Clin Breast Cancer; 2012 Feb 12; 12(1):49-56. PubMed ID: 22154118
    [Abstract] [Full Text] [Related]

  • 14. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar 12; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
    Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C.
    Br J Cancer; 2001 Jul 20; 85(2):141-6. PubMed ID: 11461067
    [Abstract] [Full Text] [Related]

  • 16. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C, Levy C, Chollet P, Merrouche Y, Roche H, Kerbrat P, Fumoleau P, Fargeot P, Clavere P, Chevallier B.
    Cancer; 2006 Dec 01; 107(11):2535-44. PubMed ID: 17054108
    [Abstract] [Full Text] [Related]

  • 17. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
    Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A.
    Oncology; 2010 Dec 01; 78(3-4):274-81. PubMed ID: 20530973
    [Abstract] [Full Text] [Related]

  • 18. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May 01; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 19. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.
    Clin Cancer Res; 2007 Apr 01; 13(7):2061-7. PubMed ID: 17404087
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 01; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.